Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22289031 | 0.86 | LMNA (0.47) | MCL1BAK1ALDH1A1MEN1KMT2A | |
| SCHEMBL31159061 | 0.83 | MCL1 (0.64) | FOLH1MCL1BAK1ALKBH1ALDH1A1 | |
| SCHEMBL31727623 | 0.83 | MCL1 (0.64) | FOLH1MCL1BAK1ALKBH1ALDH1A1 | |
| SCHEMBL27827736 | 0.82 | NOX1 (0.56) | FOLH1MCL1BAK1ALKBH1ALDH1A1 | |
| SCHEMBL31388800 | 0.82 | MCL1 (0.53) | FOLH1MCL1BAK1ALKBH1ALDH1A1 | |
| SCHEMBL1680784 | 0.80 | MAPT (0.50) | ALDH1A1NAPRT | |
| SCHEMBL29424833 | 0.79 | LTA4H (0.49) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL2191517 | 0.79 | LTA4H (0.49) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL19329183 | 0.78 | MCL1 (0.59) | FOLH1MCL1BAK1ALKBH1GRM5 | |
| SCHEMBL1680324 | 0.78 | NAPRT (0.42) | FOLH1ALDH1A1NAPRTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-119039288-A | Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12129255-B2 | Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-114245795-B | Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11919897-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2024-03-05 | — | — | US | disclosed |
| EP-3986561-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-02-14 | — | — | EP | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-3853228-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-07-28 | — | — | EP | disclosed |
| EP-3849982-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021064571-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021064571-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020254985-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254985-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020157692-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157692-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020058844-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020053811-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | POLR2H, POLR2E, EIF2AK2 | FOLH1 3928/4885MCL1 1046/4885BAK1 2367/4885 |
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DPYD | FOLH1 2606/4885MCL1 2944/4885BAK1 711/4885 |
| US-11919897-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | FOLH1 3754/4885MCL1 909/4885BAK1 1366/4885 |
| US-12129255-B2 | Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DPYD | FOLH1 2606/4885MCL1 2944/4885BAK1 711/4885 |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | FOLH1 3754/4885MCL1 909/4885BAK1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.